Search results
Jump to navigation
Jump to search
- * [[Cetuximab]] (IMC-C225) is a recombinant, human/mouse chimeric [[monoclonal antibody]] that binds to [[epidermal growth factor receptor]] (ErbB1, EGFR) and may * [[Catumaxomab]]. Is a monoclonal antibody against CD3 ([http://www.ncbi.nlm.nih.gov/sites/entrez?db=protein&term=NM_010 KB (1,356 words) - 06:07, 5 April 2024
- {{r|Monoclonal antibody}}2 KB (219 words) - 21:43, 11 January 2010
- [[Antitoxin]]s, drugs using [[monoclonal antibody|monoclonal antibodies]], etc., which directly attack or neutralize the path ...directly counteract the effects of the pathogen, as do [[antitoxin]]s or [[monoclonal antibody|monoclonal antibodies]] that kill organisms, passively add immune defensive7 KB (1,004 words) - 10:12, 30 May 2009
- }}</ref> [[monoclonal antibody]] consisting of humanized [[murine]] antibody with antigen-binding, complem3 KB (376 words) - 14:53, 17 July 2010
- The leading edge of approved treatment, however, are specific [[monoclonal antibody|monoclonal antibodies]].4 KB (541 words) - 14:37, 31 July 2010
- [[Trastuzumab]] is a [[monoclonal antibody]] against the ErbB-2 receptor that lengthens remission time in metastatic [2 KB (308 words) - 06:03, 16 July 2010
- * [[Infliximab]] (Remicade) (pronounced in flix' i mab) is a chimeric monoclonal antibody that blocks the action of TNF-alpha by binding to it.<ref>{{CZMed|Inflixima8 KB (1,138 words) - 02:03, 4 November 2010
- * [[Adalimumab]] is a [[monoclonal antibody]].2 KB (306 words) - 17:09, 26 May 2023
- ...opurine]] and [[azathioprine]], as well as [[methotrexate]]. Recently, a [[monoclonal antibody]] against [[tumor necrosis factor-alpha]], [[infliximab]], has come into us4 KB (547 words) - 16:34, 2 August 2010
- [[Rituximab]], a [[monoclonal antibody]], was found to be safe by a [[systematic review]] of 21 studies, although3 KB (477 words) - 12:55, 8 September 2020
- 3 KB (445 words) - 15:57, 28 June 2010
- ...s of the [[platelet glycoprotein GPIIb-IIIa complex]] (GPIs) include the [[monoclonal antibody]] [[abciximab]] and the small-molecule agents [[tirofiban]] and [[eptifiba4 KB (543 words) - 01:43, 8 May 2013
- ...he person's blood. Any p24 protein in the person's blood will stick to the monoclonal antibody and enzyme-linked antibody to the monoclonal antibodies to p24 causes a col26 KB (3,990 words) - 13:22, 2 February 2023
- 5 KB (667 words) - 11:08, 30 September 2011
- ...d for [[non-Hodgkin’s lymphom]]a. <sup>90</sup>Y-Ibritumomab Tiuxetan, a [[monoclonal antibody]], is currently unavailable in generic form due to its patented brand name, ...ation with radioactive <sup>90</sup>[[Yttrium]]. Ibritumomab Tiuxetan, the monoclonal antibody, is therefore coupled with a radioactively [[cytotoxic]] agent capable of d11 KB (1,563 words) - 03:38, 7 October 2013
- ...e development and control of the [[immune system]] and the production of [[monoclonal antibody|monoclonal antibodies]]21 KB (2,676 words) - 09:02, 1 March 2024
- *[[Monoclonal antibody/Definition]]15 KB (1,521 words) - 09:02, 2 March 2024
- 38 KB (5,208 words) - 09:02, 1 March 2024
- ...fit for some patients but generally do not slow disease progression. Newer monoclonal antibody treatments against beta-amyloid protein, for example, the drug Leqembi, hav15 KB (2,107 words) - 09:11, 11 May 2024
- ...ontrolled trial]], the [[relative risk ratio]] of adjunct treatment with [[monoclonal antibody|monoclonal antibodies]] against C. difficile toxins, as compared to [[place46 KB (6,252 words) - 17:10, 31 October 2013